Evidence map›Paper›PMID 42137146›Full record

ArticleFrontiers in oncology2026

Screening, validation, and mechanism study of antitumor components from

Mengjia Liang, Moyu Shen, Yuxuan Wang, Pengxin Fan, Yuguang Zheng, Haiyang Wang, Jingcun Sun, Songsong Jing

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mengjia Liang *Traditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Moyu Shen *Traditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Yuxuan WangTraditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Pengxin FanTraditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Yuguang ZhengTraditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Haiyang WangTraditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Jingcun SunDepartment of pharmacy, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hebei, Cangzhou, China.
Songsong JingTraditional Chinese Medicine Processing Technology Innovation Centre of Hebei Province, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to screen potential antitumor compounds from Methods: The chemical constituents in 12 batches of Results: A comprehensive chemical analysis was conducted on 12 batches of Conclusion: This study elucidated the key active constituents responsible for the antitumor effects of

Indexed as

A549 cellsantitumor effectDioscorea nipponica Makino subsp. rosthorniispectrum-effect relationshipUPLC-QTOF-MS

Identifiers

PMID42137146
PMCPMC13167525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.